Control of MYC translation via this mechanism through hnRNP K is significant in the context of tumorigenesis, as it has been observed that even a single CT mutation in the IRES sequence – present in 42% of myeloma multiple patients – could enhance the binding of hnRNP K to this sequence and promote an increased aberrant expression of c-Myc (52). The gene discussed is HNRNPK; the disease is plasma cell myeloma.